AD	

Award Number: DAMD17-99-2-9047

TITLE: Support for the Resident Research Associateship Program with the U.S. Army Medical Research and Material Command

PRINCIPAL INVESTIGATOR: Judith K. Nyquist, Ph.D.

CONTRACTING ORGANIZATION: National Academy of Sciences

Washington, DC 20418

REPORT DATE: November 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data geeded, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		3. REPORT TYPE AND Annual (30 Ser	DATES COVERE 0 00 - 29 s	D
4. TITLE AND SUBTITLE	November 2001	Aimual	5. FUNDING N	
Support for the Residen	t Research Associatesh	nip Program	DAMD17-99	
with the U.S. Army Medi				
-				
6. AUTHOR(S) Judith K. Nyquist, Ph.D				
baaren k. Nydarse, In.b	•		1	
7. PERFORMING ORGANIZATION NA			8. PERFORMIN REPORT NU	G ORGANIZATION
National Academy of Sci Washington, DC 20418	ences		112, 011, 140	Trib mit
washington, be 20410				
E-Mail: jnyquist@nas.edu				
		^,	40 000000	NO / MONITORING
9. SPONSORING / MONITORING AG	ENCY NAME(S) AND ADDRESS(E	S)		NG / MONITORING EPORT NUMBER
U.S. Army Medical Research and	Materiel Command		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Fort Detrick, Maryland 21702-50				
•				
44 OUDDI SASSATA DV MOTEC				
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY		1		12b. DISTRIBUTION CODE
Approved for Public Rel	ease; Distribution Un.	limited		
13. ABSTRACT (Maximum 200 Word	ds)			L
•				
•				·
14. SUBJECT TERMS				15. NUMBER OF PAGES
			F	16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSI OF ABSTRACT	FICATION	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassif	ied	Unlimited

Table of Contents

Cover
SF 298
Table of Contents
Introduction
Body
Key Research Accomplishments
Reportable Outcomes
Conclusions
References
Appendices

NATIONAL RESEARCH COUNCIL

Resident Research Associateship Program

with the

U.S. Army Medical Research and Materiel Command Annual Status Report

September 30, 2000 – September 30, 2001

DAMD17-99-2-9047

PUBLICITY

The National Research Council (NRC) Resident Research Associateship Programs for the reporting period were announced to the scientific community in the fall of the preceding year, 1999. Publicity materials describing the NRC-AMRMC Program were distributed in November to presidents, graduate deans, and heads of appropriate science and engineering departments of all academic degree-granting institutions in the United States. These materials also were sent to Laboratory Program Representatives, Associateship Advisers, and other interested persons. The publicity materials and other related information were made available on the Internet as well. In addition, Program Staff attended numerous annual society meetings to promote the various programs and meet with prospective applicants through out the year.

REQUESTS

Application materials were distributed in response to specific requests for information about the NRC-AMRMC Associateship Program or as a result of general requests by persons whose fields of specialization appeared to be appropriate for the research opportunities available in the AMRMC laboratories.

COMPETITION

Panel reviews of applicants for the Associateship Programs, including those with the U.S. Army Medical Research and Materiel Command, are conducted in February, June, and October of each year. The following is a breakdown of the action taken with the applications during the period of the report.

U.S. Army Medical Research Institute of Infectious Diseases

	Oct 00	Feb 01	Jun 01	<u>Total</u>
Total Applications	1	5	6	12
Actions taken on the applications:				
Application Too Late for Review	-	-	-	-
Applicant Withdrew before Review	-	-	-	-
Application Deferred to Next Review	-	-	-	-
Application Ineligible	-	-	-	-
Incomplete/Missing Documentation	-	-	-	-
Application Not Approved/Reviewed by Lab	-	-	-	-
Laboratory Rejection After Its Review	-	-	-	-
Active Application Pending Lab Response	-	-	-	-
Number of Applications Poviewed	1	5	6	12
Number of Applications Reviewed	•		O	12
Actions taken on the reviewed applications:				
Non-Recommended	_	_	_	-
Recommended	1	5	6	12
, togotimionada				
Actions taken on Recommended Applications:				
Applicant Accepted Award	1	3	2	6
Applicant Offered Alternate Status	_	-	-	-
Applicant Declined the Award	-	-	2	2
Applicant Withdrew After Review/Recommende	d -	1	-	1
Offer was Withdrawn by NRC	-	-	-	-
Applicant Recommended but No Action Taken	-	-	1	1
Alternate with Final Turndown	-	-	-	-
Applicant Recommended but No Funding Availa	able -	1	1	2

COMPETITION

Panel reviews of applicants for the Associateship Programs, including those with the U.S. Army Medical Research and Materiel Command, are conducted in February, June, and October of each year. The following is a breakdown of the action taken with the applications during the period of the report.

U.S. Army Institute of Surgical Research

	Oct 00	Feb 01	Jun 01	<u>Total</u>
Total Applications	2	-	2	4
Actions taken on the applications:				
Application Too Late for Review	_	_	_	_
Applicant Withdrew before Review	_	_	_	-
Application Deferred to Next Review	_	_	_	_
Application Ineligible	-	-	-	•
Incomplete/Missing Documentation	_	-	-	-
Application Not Approved/Reviewed by Lab	-	-	-	-
Laboratory Rejection After Its Review	-	-	-	-
Active Application Pending Lab Response	-	-	-	-
			0	4
Number of Applications Reviewed	2	-	2	4
Actions taken on the reviewed applications:				
Non-Recommended	_	_	_	_
Recommended	2	_	2	4
Neconinenced			_	•
Actions taken on Recommended Applications:				
Applicant Accepted Award	2	_	2	4
Applicant Offered Alternate Status	-	-	-	-
Applicant Declined the Award	-	-	-	-
Applicant Withdrew After Review/Recommender	d -	-	-	-
Offer was Withdrawn by NRC	-	-	-	-
Applicant Recommended but No Action Taken	-	-	-	-
Alternate with Final Turndown	-	-	-	-
Applicant Recommended but No Funding Availa	able -	-	-	-

COMPETITION

Panel reviews of applicants for the Associateship Programs, including those with the U.S. Army Medical Research and Materiel Command, are conducted in February, June, and October of each year. The following is a breakdown of the action taken with the applications during the period of the report.

Walter Reed Army Institute of Research

	Oct 00	Feb 01	Jun 01	<u>Total</u>
Total Applications	5	3	1	9
Astions taken on the applications:				
Actions taken on the applications: Application Too Late for Review	_		_	_
Application 100 Late for Review Applicant Withdrew before Review	_	_	_	_
Application Deferred to Next Review	_	_	-	-
Application Ineligible	_	-	_	-
Incomplete/Missing Documentation	_	-	-	-
Application Not Approved/Reviewed by Lab	-	-	-	-
Laboratory Rejection After Its Review	-	-	-	-
Active Application Pending Lab Response	-	-	-	-
.,				
	_	•	4	0
Number of Applications Reviewed	5	3	1	9
Actions taken on the reviewed applications:				
Non-Recommended	_	_	_	-
Recommended	5	3	1	9
, 1000				
Actions taken on Recommended Applications:				
Applicant Accepted Award	3	2	1	6
Applicant Offered Alternate Status	-	-	-	-
Applicant Declined the Award	-	-	-	•
Applicant Withdrew After Review/Recommende	d -	1	-	1
Offer was Withdrawn by NRC	1	-	-	1
Applicant Recommended but No Action Taken	1	-	***	1
Alternate with Final Turndown	-	-	-	-
Applicant Recommended but No Funding Availa	able -	-	-	-

ASSOCIATES' ACTIVITIES

Associates who ended tenure during the report period were on tenure for an average of 23 months, ranging from 6 months to 36 months.

Of the 22 Associates who completed their tenure during the report period, 17 (77%) submitted reports. In their termination reports, the Associates indicated the following scholarly activity while on tenure as an Associate.

26 Domestic Presentations

9 Published Articles in Refereed Journals

12 International Presentations

2 Patents applied for

After completing their tenure Associates, indicated their future plans as follows:

5 Research - National government

- Administration- government lab

6 Remain at Host Agency

- Different NRC Sponsoring Agency

2 Academic -- College or University

- Student

- Non-Profit

- Self-employed

- Unemployed

2 Industry

- Post-Doctoral Appointment

2 Other/No Information Provided

In their final reports, the Associates were asked to evaluate certain aspects of their experiences on a scale of 1 (low) to 10 (high). The average rating for each item follows.

9.4 Career: Of what value was the NRC experience to your career?

8.9 Lab: What is your evaluation of your experience in the laboratory?

9.1 NRC: What is your evaluation of your interaction with the NRC?

Advisers also were asked to complete an evaluation of the Associate. The following summarizes the Adviser evaluations for Associates completing tenure during the report period. Of the 22 number of Associates, 7 (32%) Adviser evaluations were completed. Assessments were made on four criteria using the following rating scale: 1-Below Average, 2-Average, 3-Above Average, 4-Good, and 5-Outstanding, Exceptional. The average rating for each item follows.

4.3 Knowledge in Field

4.4 Research Techniques

4.6 Independence

4.4 Motivation

The Adviser was asked, "Would you like this Associate as a Professional Colleague?" The following is a breakdown of the Adviser's response.

6 86 % Yes

- 0% No

1 14 % No Comment/No Answer

Other information about the Associates' activities can be found in the attachments and appendix.

ASSOCIATES' Citizenship

Associates on tenure as of September 30, 2000, are citizens of the following countries:

Albania	1	Israel	6
Australia	2	Italy	1
Bangladesh	1	Kenya	1
Croatia	1	Mexico	1
Ecuador	1	People's Republic of China	6
France	1	Poland	1
Ghana	1	Russia	4
Hungary	3	Ukraine	1
India	5	United States	31

Description of Attachments

Attachment 1 is a list of Associates who completed their appointments during the period of September 30, 2000, through September 30, 2001. It includes the Associates' laboratory location, their starting and termination dates, and the names of their Advisers. Associates are required to submit reports upon termination, and Advisers are asked to submit a final evaluation of each Associate. Associates who have not submitted a termination report have received a follow-up letter.

Attachment 2 provides a roster of Associates on Tenure as of October 1, 2001. This listing includes the Associate's Adviser, laboratory location, start and expected termination date, and country of citizenship.

Attachment 3 lists the applicants who received awards during the period September 30, 2000, through September 30, 2001. It includes the title of their Research Proposals.

Attachment 4 provides a roster of all recommended candidates by category (e.g., Accepted, No Funding, Declined, etc.). This report includes information about the recommended Ph.D. school, proposed research, starting date and Adviser.

Attachment 5 details a cross tabulation of how many Associates were on tenure for the year by center for each quarter within the report period and other yearly periods.

Attachment 6, if applicable, lists any of the Associates ending tenure who applied for patents, and the summary of the Associates' research.

U.S. Army Medical Research and Materiel Command

12/12/2001 Page 1 of 2

Associate Name+ Adviser	Division	Tenure Start	Dates End	Terminatio Report	n Adviser Report
Allon, Nahum(S) Dr. C. R. Alving	Division Of Biochemistry	8/01/00	7/31/01	Received	Received
Baker, Robert Owen Dr. John W. Huggins	Virology Division	1/06/00	7/16/01	Received	Not Recd
Baranyi, Lajos(S) Dr. C. R. Alving	Division Of Biochemistry	6/22/98	6/21/01	Received	Not Recd
Biba, Edmond Dr. Ai J. Lin	Division Of Experimental Therapeutics	6/28/99		Not Recd	Received
Bosio, Catharine Mans Dr. Alan L. Schmaljohn	Virology Division	9/11/00		Received	Not Recd
Bosio, Christopher Francis Dr. Alan L. Schmaljohn	Virology Division	2/04/99		Not Recd	Not Recd
Byrd, Wyatt(S) Dr. Frederick J. Cassels	Division Of Medicine	1/20/98		Not Recd	Not Recd
Dutta, Sheetij Dr. David E. Lanar	Division Of Commun Diseases/Immunology	7/27/98		Received	Not Recd
Hensley, Lisa Ellen Dr. Peter B. Jahrling	Pathology Division	9/01/98		Received	Not Recd
Hulet, Stanley Warren Dr. Tsung-Ming A. Shih	Pharmacology Division	1/10/00		Received	Not Recd
Jenner, Jennifer Louise Dr. Harris R. Lieberman	Divison not specified	6/01/98	5/31/01	Received	Not Recd
Jensen, Melody Janet(S) Dr. Leonard A. Smith	Toxinology Division	8/10/98		Not Recd	Not Recd
Kanjilal, Partha Partim(S) Dr. Richard R. Gonzalez	Divison not specified	8/02/99	7/20/01	Received	Received
Korolev, Sergey Vasilyevich Dr. Jeenan Tseng	Division Of Pathology	9/01/99		Received	Received
Kwik, Jeanne Frieda Dr. Sina Bavari	Toxinology Division	6/05/00		Received	Not Recd
Leader, Haim Nissan(S) Dr. Richard K. Gordon	Division Of Biochemistry	5/10/99		Received	Received
Markotic, Alemka Dr. Connie S. Schmaljohn	Virology Division	10/25/99	10/24/00	Received	Not Recd
Marvaud, Jean-Cristophe Dr. Leonard A. Smith	Toxinology Division	12/01/99		Received	Received
Mendelson, Itai(S) Dr. Arthur M. Friedlander	Bacteriology Division	4/24/00	6/30/01	Received	Received
Rayner, Jonathan Ole Dr. Jonathan F. Smith	Virology Division	5/01/00	10/31/00	Received	Not Recd
Waitumbi, John Njenga(S) Dr. Jose A. Stoute	Medical Research Unit-Kenya	2/09/98	2/08/01	Received	Not Recd

^{+ (}S) indicates the associate was a Senior.

Associates Who Ended Tenure 9/30/2000 - 9/30/2001

Attachment 1

U.S. Army Medical Research and Materiel Command

12/12/2001 Page 2 of 2

Associate Name+	Division	Tenure Dates	_	Termination Adviser	
Adviser		Start Er	d Report	Report	
Weeks, Steven Douglas Dr. Susan L. Welkos	Bacteriology Division	5/04/98 5/0	3/01 Not Recd	Not Recd	

22 Associates Listed

^{+ (}S) indicates the associate was a Senior.

U.S. Army Medical Research and Materiel Command

12/12/2001 Page 1 of 3

Associate Name+ Adviser	Division Citizenship	Starting Date	Ending Date
Ayyagari, Vijay Lakshmi Naga	Division Of Medicine	7/03/00	7/02/02
Dr. Jayasree Nath	India		
Babai, Ilan	Division Of Biochemistry	7/17/00	7/16/02
Dr. C. R. Alving	Israel		
* Batchinsky, Andriy Ivanovich	974000 Not found	1/09/01	1/08/03
Dr. Leopoldo C. Cancio	Ukraine		
Bodo, Michael Mihaly (S)	Division Of Surgery	2/14/00	2/13/02
Dr. Frederick J. Pearce	Hungary		
* Cohen, Sara (S)	Division Of Commun Diseases/Immunology	8/02/01	8/01/02
Dr. Luther E. Lindler	Israel		
Darko, Christian Asare	Division Of Commun Diseases/Immunology	11/09/98	5/08/02
Dr. Jeffrey A. Lyon	Ghana		
Dekonenko, Alexander Evgenievich	Virology Division	11/02/98	11/01/01
Dr. Connie S. Schmaljohn	Russia		
Dillman, James F., III	Pharmacology Division	11/29/99	11/28/02
Dr. John J. Schlager	United States		
Dow, Geoffrey Stuart	Division Of Experimental Therapeutics	8/07/00	8/06/02
Dr. Rodger K. Martin	Australia		
Erwin, James Lawrence	Pathology Division	8/10/98	2/09/02
Dr. Tran C. Chanh	United States		
* Fisher, Robert Walt St. George, IV	Virology Division	3/14/01	3/13/02
Dr. Kevin Anderson	United States		
* Fleming, Sherry D.	Division Of Medicine	1/02/01	1/01/02
Dr. George C. Tsokos	United States		
* Godkar, Praful Babaji	Walter Reed Army Institute of Research	2/23/01	2/22/02
Dr. Haresh Ved	India		
* Gonzalez, Liza Marie	Virology Division	1/08/01	1/07/02
Dr. Connie S. Schmaljohn	Italy		
* Gooch, Jan Woodall (S)	974000 Not found	7/23/01	7/22/02
Dr. Albert T. McManus	United States		
* Gorbounov, Nikolai Viktorovich (S)	Division Of Medicine	10/10/00	10/09/02
Dr. Jayasree Nath	US Permanent Resident		
Grogan, Case Kyn	Virology Division	6/26/00	6/25/02
Dr. Alan L. Schmaljohn	United States		
Guerrero-Ontiveros, Maria de Lourde	Division Of Commun Diseases/Immunology	2/16/99	2/15/02
Dr. Luther E. Lindler	Mexico		
* Heller, Elimelech Dan (S)	Division Of Commun Diseases/Immunology	10/02/00	10/01/01
Dr. Marcia K. Wolf	Israel		
* Hillier, Collette Jane	Division Of Commun Diseases/Immunology	2/12/01	2/11/02
Dr. David E. Lanar	Australia		
* Islam, Dilara (S)	Armed Forces Res Inst Med Sci-Bangkok	9/04/01	9/03/02
Dr. Ladaporn Bodhidatta	Bangladesh		
Kan, Robert Kwai	972500 Not found	5/10/99	5/09/02
Dr. John P. Petrali	United States		

^{*}Indicates that the associate started tenure between 10/1/2000 and 9/30/2001.

⁽S) Associate is a Senior.

U.S. Army Medical Research and Materiel Command

12/12/2001 Page 2 of 3

Associate Name+ Adviser	Division Citizenship	Starting Date	Ending Date
k LaJambe, Cynthia Marie	Walter Reed Army Institute of Research	1/03/01	1/02/02
Dr. Nancy J. Wesensten	United States		
Leon Villalba, Luis Renato	Virology Division	5/25/00	11/24/01
Dr. Michael J. Turell	Ecuador		
Liu, Liang Ming	974000 Not found	4/08/99	10/07/01
Dr. Michael A. Dubick	People'S Republic Of China		
* McElroy, Anita Katherine	Virology Division	4/05/01	4/04/02
Dr. Connie S. Schmaljohn	United States		
Milosevits, Janos (S)	Division Of Biochemistry	7/03/00	7/02/02
Dr. C. R. Alving	Hungary		
Myers, Todd Matthew	Division of Neurosciences	5/15/00	5/14/02
Dr. Richard A. Bauman	United States		
* Nair, Lalitha Punchayil Velayudhan	(SDivision Of Commun Diseases/Immunology	10/11/00	10/10/02
Dr. David E. Lanar	India		
* Olinger, Gene Garrard, Jr	Virology Division	6/04/01	6/03/02
Dr. Mary K. Hart	United States		
* Paragas, Jason Jared	Virology Division	7/24/01	7/23/02
Dr. Michael Bray	United States		
* Peachman, Kristina Kathryn	Division Of Biochemistry	6/01/01	5/31/02
Dr. C. R. Alving	United States		
Peng, Daizhi (S)	974000 Not found	1/05/99	5/04/02
Dr. Albert T. McManus	People'S Republic Of China		
Riemenschneider, Jenny Lynn	Virology Division	3/01/00	2/28/02
Dr. Connie S. Schmaljohn	United States		
Roberson, Melinda Rice	Pharmacology Division	5/02/00	5/01/02
Dr. John H. McDonough	United States		
* Savransky, Vladimir (S)	Division Of Pathology	2/12/01	2/11/02
Dr. Jeenan Tseng	Russia		
* Steffen, Scott Edward	Virology Division	1/02/01	1/01/02
Dr. Connie S. Schmaljohn	United States		
* Swietnicki, Wieslaw, Sr (S)	Toxinology Division	6/01/01	5/31/02
Dr. Robert G. Ulrich	US Permanent Resident	- 1-0 10 4	0.100.100
* Tang, Qidong (S)	974000 Not found	3/29/01	3/28/02
Dr. Phillip D. Bowman	People'S Republic Of China	4 /0 4 /0 0	4 /00 /00
Troyer, Jill Michelle	Walter Reed Army Institute of Research	1/04/99	1/03/02
Dr. Daniel A. Strickman	United States	m 14 < 10 4	# /1 F /00
* Ulrich, Ricky Lee	Bacteriology Division	7/16/01	7/15/02
Dr. Patricia L. Worsham	United States	0.10.0.10.0	0.44.0.40.0
Weyand, Peter Gregory (S)	973000 Not found	9/20/99	9/19/02
Dr. Reed W. Hoyt	United States	= 15.0 10.0	# 10 = 10 o
Winter, David Bicknell (S)	Division Of Medicine	7/28/00	7/27/02
Dr. George C. Tsokos	United States	4100104	4100100
* Yuan, Huijun	Division Of Biochemistry	4/09/01	4/08/02
Dr. C. R. Alving	People'S Republic Of China		

^{*}Indicates that the associate started tenure between 10/1/2000 and 9/30/2001.

⁽S) Associate is a Senior.

Associates On Tenure

October 1, 2001

Attachment 2

U.S. Army Medical Research and Materiel Command

12/12/2001 Page 3 of 3

Associate Name+ Adviser	Division Citizenship	Starting Date	Ending Date
Zhang, Peng (S)	Division Of Biochemistry	2/01/99	1/31/02
Dr. Peter K. Chiang Zhu, Shuren	US Permanent Resident Division Of Experimental Therapeutics	11/01/99	10/31/02
Dr. Ai J. Lin	US Permanent Resident		

^{*}Indicates that the associate started tenure between 10/1/2000 and 9/30/2001. (S) Associate is a Senior.

Applicants Who Received Awards

9/30/2000 - 9/30/2001

AMRMC - Medical Research Institute of Infectious Diseases

Attachment 3
12/12/2001 Page 1 of 3

Name/

Research Title

October 2000 Awardees

Awardees Listed 1

Fisher, Robert W, IV

Analysis of Differential Cellular Gene Expression to Define New Targets for Therapeutic Intervention for Viral Hemorrhagic Fevers

February 2001 Awardees

Awardees Listed 3

McElroy, Anita K

Viral and Cellular Factors Mediating Hantavirus Pathogenesis and Persistence

Olinger, Gene G, Jr

Identification of Ebola Proteins that Elicit Cell-Mediated Immunity for Use in a Cocktail Vaccine Strategy Using Venezuelan Equine Encephalitis Virus Replicons

Swietnicki, Wieslaw, Sr

Engineering of Spe-C Superantigen for use as a Vaccine Against Streptococcus Pyogenes

June 2001 Awardees

Awardees Listed 2

Paragas, Jason J

Rational Development of Ebola Virus Antiviral Targets

Ulrich, Ricky L

Using Proteomics To Create Molecular Fingerprints for the Causative Agents of Plague, Anthrax, Glanders and Melioidosis

Total Associates Listed for Center 6

* * *

Applicants Who Received Awards

9/30/2000 - 9/30/2001

AMRMC - U.S. Army Institute of Surgical Research

Attachment 3

12/12/2001 Page 2 of 3

Name/

Research Title

October 2000 Awardees

Awardees Listed 2

Batchinsky, Andriy I

Effective of Extremity Ischemia and Reperfusion on Muscle and Nerve Physiology in a Porcine Model

Tang, Qidong

Transcriptional Response of Human Umbilical Vein Endothelial Cells to Hypoxic Injury and Development of Protective

June 2001 Awardees

Awardees Listed 2

Gooch, Jan W

Biocompatible Hydrophilic Films from Acrylic Mini-emulsions: Protection of Wounds

Yershov, Andrey L

Blunt Trauma and Burn Injury as Predisposing Factors for Developing Pneumonia in Ventilated Patients

Total Associates Listed for Center 4

* * *

Applicants Who Received Awards

9/30/2000 - 9/30/2001

AMRMC - Walter Reed Army Institute of Research

Attachment 3

12/12/2001 Page 3 of 3

Name/

Research Title

October 2000 Awardees

Awardees Listed 3

Fleming, Sherry D

Role of Complement Inhibitors in Mesenteric Ischemia-Reperfusion Injury

LaJambe, Cynthia M

Chronotype Contributions to Sleep-Deprivation Decrements in Cognitive Performance and Alertness

Savransky, Vladimir

Mucosal Immune Responses to Staphylococcal Enterotoxin B (SEB) Mutants Cloned into Lactobacillus Casei

February 2001 Awardees

Awardees Listed 2

Cohen, Sara

Universal ORF Plasmid Library for Directed Mutagenesis of Potential Virulence Genes in Y.pestis, F.tularensis and B.melitensis Bacteria

Peachman, Kristina K

Transcutaneous HIV Vaccines

June 2001 Awardees

Awardees Listed 1

Islam, Dilara

Establishment of the Immunological Assays for Shigella-Vaccine Trial and To Explore the Role of Specific and Innate Mechanisms of Immune Responses in Vaccinees

Total Associates Listed for Center 6

* * :

Recommended Candidates

9/30/2000 - 9/30/2001

AMRMC- Medical Research Institute of Infectious Diseases

Attachment 4 12/12/2001 Page 1 of 6

October 2000

A- Accepted Award

FISHER, ROBERT W, IV

Ph D. Date: 2000

Citizenship: Adviser:

United States

U of North Carolina-Chapel Hill

Actual Starting Date:

3/14/01

Research Field: Molecular Pathology

Dr. Kevin Anderson

Termination Date:

3/13/02

Research Title:

Analysis of Differential Cellular Gene Expression to Define New Targets for Therapeutic Intervention for Viral Hemorrhagic Fevers

February 2001

A- Accepted Award (3 Applicants listed)

MCELROY, ANITA K

Ph.D. Date: 2000

United States

Univ of California-San Diego

Actual Starting Date:

4/05/01

Adviser:

Citizenship:

Dr. Connie S. Schmaljohn

Research Field: Virology

Termination Date:

4/04/02

Research Title:

Viral and Cellular Factors Mediating Hantavirus Pathogenesis and Persistence

OLINGER, GENE G, JR

Citizenship:

United States

Ph.D. Date: 2001

Rush University/IL

6/04/01

Adviser:

Dr. Mary K. Hart

Actual Starting Date:

Research Field:

Viral Immunology

Termination Date:

6/03/02

Research Title:

Identification of Ebola Proteins that Elicit Cell-Mediated Immunity for Use in a Cocktail Vaccine

Strategy Using Venezuelan Equine Encephalitis Virus Replicons

SWIETNICKI, WIESLAW, SR

Citizenship:

Poland

Ph.D. Date: 1995

University of Florida

Adviser:

Dr. Robert G. Ulrich

Actual Starting Date:

6/01/01

Termination Date:

5/31/02

Research Title:

Research Field: Biochemistry

Engineering of Spe-C Superantigen for use as a Vaccine Against Streptococcus Pyogenes

W- Withdrew after Review/Recommend

O'SULLIVAN, CHRISTOPHER T

Ph.D. Date: 2001

Johns Hopkins University/MD

Citizenship:

United States

Adviser:

Dr. Sina Bavari

Research Field:

Virology The Role of Lipid Raft Microdomains in Cellular Infection and Budding by Marburg Virus Research Title:

12/12/2001 Page 2 of 6

AMRMC- Medical Research Institute of Infectious Diseases

Z-Recommended/No Funding

THEREGOWDA, VEERABASAPPA G

Ph.D. Date: 1973

Citizenship:

India

University of Mysore/India

Adviser:

Dr. Leonard A. Smith

Research Field: Biochemistry

Research Title:

Development of Therapeutic Interventions Against Botulism

June 2001

1- Recommended

SHURTLEFF, AMY C

Ph.D. Date: 2002

U of Texas, Medical Br-Galveston

Citizenship:

United States

Adviser:

Dr. Mary C. Guttieri

Research Field: Molecular Virology

Research Title: Development of Human Monoclonal Antibody Therapy for Lassa Fever

A- Accepted Award (2 Applicants listed)

PARAGAS, JASON J

Ph.D. Date: 2001

Citizenship: Adviser:

United States Dr. Michael Bray Mt Sinai School of Medicine-CUNY Actual Starting Date:

Research Field: Virology

Termination Date:

7/24/01 7/23/02

Research Title:

Rational Development of Ebola Virus Antiviral Targets

ULRICH, RICKY L

Ph.D. Date: 1999

Citizenship:

United States

Clemson University/SC

Adviser: Research Field: Bacteriology

Dr. Patricia L. Worsham

Actual Starting Date:

Termination Date:

7/16/01 7/15/02

Research Title:

Using Proteomics To Create Molecular Fingerprints for the Causative Agents of Plague, Anthrax,

Glanders and Melioidosis

8- Declined (2 Applicants listed)

KERCHER, LISA A

Ph.D. Date: 2001

Citizenship:

United States

Baylor College of Medicine/TX

Adviser:

Dr. Mary K. Hart Research Field: Molecular Virology

Research Title: Maturation and Function of the Venezuelan Equine Encephalitis (VEE) Virus Glycoprotein E3

PETRO, JAMES B

Ph.D. Date: 2001

Vanderbilt University/TN

Citizenship: Adviser:

United States

Dr. Erik A. Henchal

Research Field: Immunology

Research Title: Characterization of Cellular Gene Expression Induced by Yersinia Pestis Infection

Recommended Candidates

9/30/2000 - 9/30/2001

AMRMC- Medical Research Institute of Infectious Diseases

Attachment 4 12/12/2001 Page 3 of 6

Z- Recommended/No Funding

HURRELBRINK, ROBERT J

Ph.D. Date: 2001

Citizenship:

Australia

Western Australia, U

Adviser:

Dr. Kevin Anderson

Research Field: Virology

Research Title:

Intertypic Chimeras, Site-Directed Mutagenesis and Gene Rearrangement as Molecular Genetic approaches to Ebola Virus Vaccine Development

AMRMC- U.S. Army Institute of Surgical Research

12/12/2001 Page 4 of 6

October 2000

A- Accepted Award (2 Applicants listed)

BATCHINSKY, ANDRIY I Ph.D. Date: 1994

Citizenship: Ukraine Uzhgorod Municipal Hosp/Ukraine
Adviser: Dr. Leopoldo C. Cancio Actual Starting Date: 1/09/01
Research Field: Cell Physiology Termination Date: 1/08/03

Research Title: Effective of Extremity Ischemia and Reperfusion on Muscle and Nerve Physiology in a Porcine

Model

TANG, QIDONG Ph.D. Date: 1993

Citizenship: People's Republic of China Sun Yat-Sen Univ of Med Sci/China
Adviser: Dr. Phillip D. Bowman Actual Starting Date: 3/29/01
Research Field: Medical Research
Termination Date: 3/28/02

Research Title: Transcriptional Response of Human Umbilical Vein Endothelial Cells to Hypoxic Injury and

Development of Protective Means

June 2001

A- Accepted Award (2 Applicants listed)

GOOCH, JAN W Ph.D. Date: 1980

Citizenship: United States Univ of Southern Mississippi

Adviser: Dr. Albert T. McManus Actual Starting Date: 7/23/01
Research Field: Material Science Termination Date: 7/22/02
Research Title: Biocompatible Hydrophilic Films from Acrylic Mini-emulsions: Protection of Wounds

YERSHOV, ANDREY L Ph.D. Date: 1992

Citizenship: Russia St Petersburg Acad Postgrad Edu
Adviser: Dr. Michael A. Dubick Actual Starting Date: 10/15/01
Research Field: Microbiology Termination Date: 10/14/02

Research Title: Blunt Trauma and Burn Injury as Predisposing Factors for Developing Pneumonia in Ventilated

* * *

Patients

12/12/2001 Page 5 of 6

AMRMC- Walter Reed Army **Institute of Research**

October 2000

1- Recommended

COX, DONNA S

Ph.D. Date: 2000

Citizenship:

United States

U of Maryland-Baltimore County

Adviser:

Dr. Gary H. Kamimori

Research Field:

Pharmacology

Research Title:

Pharmacokinetics and Pharmacodynamics of Caffeine Administered by a Multiple Dosing Regimen

via a Novel Formulation

A- Accepted Award (3 Applicants listed)

FLEMING, SHERRY D

Ph.D. Date: 1998

Citizenship:

United States

University of Colorado-Denver

Actual Starting Date:

1/02/01

Adviser: Research Field: Immunology

Dr. George C. Tsokos

Termination Date:

1/01/02

Research Title:

Role of Complement Inhibitors in Mesenteric Ischemia-Reperfusion Injury

LAJAMBE, CYNTHIA M

Ph.D. Date: 2000

Citizenship:

United States

The Pennsylvania State University **Actual Starting Date:**

1/03/01

Adviser:

Dr. Nancy J. Wesensten Research Field: Biobehavioral Sciences

Termination Date:

1/02/02

Research Title:

Chronotype Contributions to Sleep-Deprivation Decrements in Cognitive Performance and

Alertness

SAVRANSKY, VLADIMIR

Ph.D. Date: 1994

Citizenship:

Russia Dr. Jeenan Tseng St. Petersburg State Univ/Russia **Actual Starting Date:**

Adviser: Research Field:

Immunology

Termination Date:

2/11/02

Research Title:

Mucosal Immune Responses to Staphylococcal Enterotoxin B (SEB) Mutants Cloned into

Lactobacillus Casei

X-NRC Withdrew Award

BOYAPATY, GOKUL

Ph.D. Date: 2000

Citizenship:

Indian Inst of Technology, Madras

Adviser:

Dr. Peter K. Chiang

Research Field:

Immunology

Research Title:

Recombinant Expression of an MHC Class II Binding Epitope of Staphylococcal Enterotoxin B in

E Coli and S Aureus

February 2001

A- Accepted Award (2 Applicants listed)

COHEN, SARA

Ph.D. Date: 1979

Citizenship:

Israel

Tel Aviv University/Israel

Adviser:

Actual Starting Date: Dr. Luther E. Lindler

8/02/01

Research Field: Microbial Genetics

Termination Date:

8/01/02

Research Title:

Universal ORF Plasmid Library for Directed Mutagenesis of Potential Virulence Genes in Y.pestis, F.tularensis and B.melitensis Bacteria

Attachment 4 12/12/2001 Page 6 of 6

AMRMC- Walter Reed Army Institute of Research

PEACHMAN, KRISTINA K

Ph.D. Date: 2000

Citizenship:

United States

Wake Forest University/NC

Adviser:

Dr. C. R. Alving

Actual Starting Date:

6/01/01

Research Field:

Viral Immunology

Termination Date:

5/31/02

Research Title:

Transcutaneous HIV Vaccines

W- Withdrew after Review/Recommend

REBEIL, ROBERTO

Ph.D. Date: 2001

Citizenship:

United States

University of Arizona

Adviser:

Dr. Luther E. Lindler

Research Field: Bacteriology

Research Title:

Genomic Substractive Hybridization of Yersinia pestis

June 2001

A- Accepted Award

ISLAM, DILARA

Ph.D. Date: 1995

Citizenship:

Bangladesh

Caroline Inst Actual Starting Date:

Adviser:

Dr. Ladaporn Bodhidatta

9/04/01

Research Field:

9/03/02

Immunology

Termination Date:

Research Title:

Establishment of the Immunological Assays for Shigella-Vaccine Trial and To Explore the Role of Specific and Innate Mechanisms of Immune Responses in Vaccinees

U.S. Army Medical Research and Materiel Command

		Number	of Associa	tes on tent	ire as of	
Division	9/30/99	9/30/00	12/31/00	3/31/01	6/30/01	9/30/01
972500 Not found	1	1	1	1	1	1
973000 Not found	3	3	3	3	2	1
974000 Not found	2	2	2	4	4	5
Armed Forces Res Inst Med Sci-Bangkok	-	-	-	-	-	1
Bacteriology Division	2	2	2	2	1	1
Division Of Biochemistry	5	6	5	5	6	5
Division Of Commun Diseases/Immunology	5	3	5	6	6	6
Division Of Experimental Therapeutics	1	3	3	3	3	2
Division Of Medicine	1	3	4	4	4	4
Division of Neurosciences	-	1	1	1	1	1
Division Of Pathology	1	1	1	2	1	1
Division Of Surgery	-	1	1	1	1	1
Medical Research Unit-Kenya	1	1	1	-	-	-
Pathology Division	2	2	1	1	1	1
Pharmacology Division	2	3	3	3	3	2
Toxinology Division	3	2	1	1	2	1
Virology Division	4	9	7	10	12	10
Walter Reed Army Institute of Research	1	1	1	3	3	3
	34	44	42	50	51	46

Attachment 6

12/12/2001 Page 1 of 1

U.S. Army Medical Research and Materiel Command

Dutta, Sheetij 7/27/1998 7/26/2001

Patent Title: Process for Expression and Purification of Plasmodium vivax MSP1-p42 Expressed in Escherichia coli.

Co-authors: David E. Lanar, Sheetij Dutta and Lisa A. Ware

Date Applied For:

3/19/2001

Date Approved For:

2 Patent Title: Process for Purification of Recombinant plasmodium falciparum AMA-1 from E. coli.

Co-authors: David E. Lanar, Sheetij Dutta, Lalith Nair and Lisa A. Ware

Date Applied For:

3/26/2001

Date Approved For:

Korolev, Sergey Vasilyevich 9/01/1999 4/14/2001

Patent Title:

Co-authors:

Date Applied For:

Date Approved For:

2 Patent Title:

Co-authors:

Date Applied For:

Date Approved For:

12/12/2001 Page 1 of 7

U.S. Army Medical Research and Materiel Command

Allon, Nahum

8/01/2000 7/31/2001

- 2 A plasmid containing human butyrylcholinesterase gene was successfully encapsulated in small unilamelar liposomes (150-200nm) with high efficiency (>60%). The encapsulated liposomes were purified from the non encapsulated DNA.
- 4 Fusion peptides were designed synthetized and tested in in-vitro and in-vivo system. The fusion peptides are designed to change their conformation due to changes in the pH and thus disrupt the endosomal membrane and release the plasmid.
- 6 Six targeting peptides for lung cells were designed and tested for their selectivity to various lung cell lines.
- Various linkers for the conjugation between the peptides and the liposomes were tested. The direct linkage to the phospholipid was finally adopted for further research.
- An animal model using an otoscopic intra-trachealy instillation of liposomes containing plasmid were tested and adopted for the in-vivo testing of the delivery system.

Baker, Robert Owen

1/06/2000 7/16/2001

- 1 GFP expressed from vaccinia virus can be used as a simple and rapid reporter for virus growth. This system can be used to test antiviral drugs, and viral growth curves were obtained from single plates assayed on consecutive days with minimal handling.
- 3 Lesional and lethal models for both monkeypox and smallpox were developed by i.v. injection of virus into monkeys. These models are still being characterized. These models will allow the testing of antiviral drugs in vivo for possible FDA approval.
- 5 The DNA polmerase gene form 45 strains of Variola Virus were cloned and are being sequenced to determine possible sources for observed differences in drug sensitivities.
- 7 Some 800 potential antiviral drugs have been tested against a panel of pox viruses, including smallpox, moneypox, cowpow, camelpox, and vaccinia viruses. Some of the most active of these drugs are being tested in animal models.
- 8 Progress was made towards rodent models of camelpox and monkeypox. If these systems can be validated, it will minimize the need for either large animals or non-human primates in drug testing.

Baranyi, Lajos

6/22/1998 6/21/2001

- 1 We showed that the pseudo allergic reactions to liposomes are the result of the ability of the microvesicles to activate the complement system in pigs, rates and humans, due to naturally occurring antibodies as well as direct complement activation.
- 2 Release of the anaphylatoxins, especially the C5a during the complement activation is the major component of the observed reaction.

U.S. Army Medical Research and Materiel Command

- 3 We found that changing the size and composition of lipids in the liposomes affects highly the ability of liposomes to activate the complement system and therefore their ability to induce the adverse reactions termed CARPA.
- We determined a new formulation of liposomes that have a reduced ability to activate complement and established a strong complement activator liposome for testing the effects of complement activation in new animal models.
- 5 We were successful in developing a new drug candidate, a C5a receptor inhibitor. A highly potent antagonist of C5a receptor was developed by oligomerizing 226-LLRTWSRRATSTKTLKV using a MAP resine resulting in a potent C5a receptor inhibitor.

Bosio, Catharine Mans

9/11/2000 8/31/2001

- 1 Primary human dendritic cells were cultured and successfully infected with both Marburg and Ebola viruses. I demonstrated that dendritic cells were susceptible to infection but were also suitable for logarithmic growth of both viruses.
- 2 Cytokine profiles from Ebola and Marburg infected dendritic cells revealed that, unlike many other pathogens, neither of these viruses induced secretion of essential proinflammatory cytokines, including TNF-alpha, IL-10, IFN-alpha, IL-6 and IL-1beta.
- 3 I demonstrated that both Ebola and Marburg viruses specifically interfered with the ability of dendritic cells to secrete IFN-alpha and not other proinflammatory cytokines such as TNF-alpha and IL-6.
- 4 Additionally, I produced evidence that Ebola and Marburg viruses interfered with the ability of dendritic cells to stimulate T lymphocytes following exposure to irradiation inactivated Ebola or Marburg virus.
- 5 Dendritic cells were also shown to be capable of infection with VEE replica particles encoding a variety of antigens.

Dutta, Sheetij

7/27/1998 7/26/2001

- 1 Developed a process for the production of human vaccine grade P. vivax Merozoite surface protein 42 kDa fragment. Immunigenicity of the expressed product in mice was done and is being tested in Rhesus monkeys.
- 2 Developed a process for the production of human vacccine grade P. falciparum Apical membrane antigen-1. Antigen was vialed under cGMP conditions and is awaiting human testing at WRAIR. Also various bichemical tests for an IND submission were done.
- 3 Expressed the P. vivax Merozoite surface protein 42 kDa fragment in the Venezualan equine encephelitis virusm system. The virons are being evaluated for immunogenicity in mice.
- 4 Expressed the P. vivax Duffy binding protein region II in the baculovirus system, the protein was purified and was tested for its RBC binding properties.

U.S. Army Medical Research and Materiel Command

5 Expressed the P. cynomolgi Merozoite surface protein -1 42 kDa fragment in bacterial system and the purified protien was tested for immunogenicity in mice. The protein ias being tested in Rhesus monkeys for protective potential against the parasite.

	potential against the parasite.
Hei 1	Development of a detection assay for Simian Hemmorrhagic fever.
2	Identification of apoptosis as the mechanism of cell death in Ebola infections of non-human primates.
3	Identification of apoptotic genes that may be involved in triggering apoptosis during Ebola infections.
4	Detection of cytokines and chemokines in vitro and in vivo Ebola infections.
5	Detection of tissue factor in Ebola infected non-human primates.
Hu 1	let, Stanley Warren 1/10/2000 9/28/2001 0.4 and 0.5 x LD50 GB can be injected (s.c.) into guinea pigs 1 per day for 2 weeks (Mon-Fri) without eliciting cortical EEG seizures.
3	Dose related decreaes in body weight gain and red blood cell acetylcholinesterase were observed.
5	While there were no obvious signs of nerve agent intoxication in the animals receiving 0.4 x LD50 GB there were subtle neurobehavioral changes observed with a functional observational battery.
7	After 10 days recovery from GB exposure baseline choline levels where depressed compared to baseline levels in control animals and there was an increase acetychloline release in response to atropine challenge.
9	There were decreased in power of low frequency Delta and Theta EEG recordings, as compared to saline controls which were still identifiable 6 days after the last GB injection.

12/12/2001 Page 4 of 7

U.S. Army Medical Research and Materiel Command

Jenner, Jennifer Louise

6/01/1998 5/31/2001

- 1 A single twenty minute bout of eccentric exercise on a specially designed motorized cycle ergometer is an excellent model for studying military training-related musculoskeletal injuries in soldiers.
- 2 There was no significant difference between the placebo and antioxidant supplemented groups with respect to muscle injury (assessed by serum creatine kinase and myoglobin) or muscle recovery (assessed by muscle power and force).
- 3 Subjects consuming the supplement did not experience significantly improved mood states (assessed by Profile of Mood States Questionnaires) during recovery from muscle injury compared to the placebo group.
- 4 Delayed Onset muscle Soreness scores were not significantly different between the antioxidant and placebo group for any of the recovery days.
- 5 Supplementation with vitamin C and E (400 mg/day and 800 mg/day, respectively) for four weeks prior to and one week following a single bout of eccentric cycling exercise did not appear to offer protection against muscle damage or enhance recovery.

Kanjilal, Partha Partim

8/02/1999 7/20/2001

- Variability of the Blood Pressure pattern or wave-shape can reflect state of cardiovascular condition through linear spectral analysis and nonlinear analysis of weighted singular value distribution profiles of the signal against surrogates.
- 4 Analysis of data obtained from animal studies show distinct correlation between the spectral characteristics of the ECG signal and the thermal accimation state, which may be usable as a signature of the state of heat-acclimation.
- 6 Nonlinear analysis of the Pulse Transit Time (PTT) series shows that there is a strong link between PTT and the level of blood pressure of the subject.
- 7 Singular value ratio spectrum can also be obtained by Singular value decomposition of rank-ordered information matrices instead of matrices fromed by the successive segments of actual data.

Korolev, Sergey Vasilyevich

9/01/1999 4/14/2001

- 2 Ten mutants of staphylococcal enterotoxin B (SEB) have been developed with histidine residues replaced by tyrosine residues at different positions. All SEB mutants were cloned into plasmid pET22B(+) and expressed in E.coli as soluble proteins.
- 4 The antigenic determinant feature of the mutant proteins decreases as the number of replaced histidine residues increased, which was shown by immunoblotting on the periplasmic fractions extracted from the mutants.
- 6 Detailed protocol of purification has been developed for SEB proteins (both intact and mutant) from E.coli. The SEB proteins can be isolated by FPLC using red-dye A column and mono Q column.

12/12/2001 Page 5 of 7

U.S. Army Medical Research and Materiel Command

Set of different cassettes of expression (shuttle vectors) has been developed for production of heterologous proteins in L.casei and established expression of SEB genes in Lactobacillus casei.

Kwik, Jeanne Frieda

6/05/2000 8/31/2001

- 1 Superantigens which crosslink MHC II, such as SEA or SEE, utilize discrete membrane domains called lipid rafts, while non-crosslinking superantigen toxicity is not dependent upon lipid raft integrity.
- 3 Gamma/delta T cells expand after Marburg protein application.
- 4 TLR1 expression is enhanced on THP-1 cells after Marburg protein application.

Leader, Haim Nissan

5/10/1999 11/09/2000

- 1 Synthesis and purification of all phosponylated oximes (POX'S) which are derived from the interaction of nerve agents (GB,GD,GFL,VX) with mono-pyridinium oxime reactivators (2-PAM and 4-PAM).
- 2 Synthesis and isolation of POX's derived from the interaction of the above nerve agents with bis-pyridinium oxime reactivators such as Toxogonin, TMB-4 and HI-6.
- 3 Biochemical charactaerisation (enzomology and toxicology) of the synthtic POX'S.

Markotic, Alemka

10/25/1999 10/24/2000

- Proinflammatory cytokines and chemokines and their receptors may play an important role in immunopathogenesis of hemorhagic fever wit renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS).
- 2 There are differences in cytokine/chemokine profile and dynamics betwee HFRS and (HPS) viruses.
- 3 We could also observe the differences between the viruses which caused the same sndrome as well as some similarities between the viruses which cause different syndromes.

U.S. Army Medical Research and Materiel Command

	~·
4	RANTES and RANTES receptors may play an iportant role in the pathogenesis of HFRS and HPS.
6	Hantaviruses are able to induce apoptosis in 293HEK cells.
Ma 1	rvaud, Jean-Cristophe 12/01/1999 11/30/2000 Characterization of iota toxin domains.
2	Purification of single chain fragment variable against light chain botulinum toxin.
Me 2	ndelson, Itai 4/24/2000 6/30/2001 Nineteen target ORFs were selected, using the available B. anthracis preliminary sequence database from TIGR Website and various programs available from the NCBI Web site.
3	The target ORF DNA fragments and the parallel unique DNA-tags were linked and cloned into the temperature-sensitive-suicide pDSTM vector (developed in IIBR, formerly named pEO-3).
4	The library of ts-suicide pDSTM-vectors, carrying different PCR amplified tagged-ORF1N fusions, was used to transform B. anthracis Ames cells.
5	Detailed protocols aimed to induce the curing of pDSTM from transformed B. anthracis Ames cells and to select for the integration events were developed.
6	Five B. anthracis mutants were generated by directing the knockout of four chromosomal targets and one pXO1 gene (pagA that encodes the protective antigen).

Rayner, Jonathan Ole

5/01/2000 10/31/2000

- 1 Developed negative strand VEE replicon and assessed its utility in trans.
- 2 Developed VEE replicon expressing a puromycin resistance gene for stable virus production.

12/12/2001 Page 7 of 7

U.S. Army Medical Research and Materiel Command

Waitumbi, John Njenga	2/09/1998	
1 Red blood cells of children with severe malaria anemia CR1 and CD55.	have reduced	d expression of complement regulatory proteins

- 2 Severe malarial anemia emanates from cumulative damage to the RBC surface membrane.
- 3 The level of expression of erythrocyte CR1 and CD55 is age dependent, being lowest in age grup most susceptible to severe malaria anemia.
- 4 The level of expression of erythrocyte CR1 and CD55 is highest in children who develop cerebral malaria.
- 5 Red blood cells with reduced CR1 and CD55 are liable to classical complement mediated lysis.

U.S. Army Medical Research and Materiel Command For Associates Who Ended Tenure Between

12/12/2001 Page 1 of 3 [r_term_summary].

Name	Id Number	Level	Start	Dates Term	Mnths*	Journal Articles	Presentations Domestic Intl	tions Intl	Patents	Know	Tech	Motiv	Rsch	Colleg
			Term Rpt Received	ξ p		Career	Lab	NRC		Post-Tenure Plans)
Allon, Nahum	0038180	Senior	8/01/00	7/31/01	12	ı			1	5	5	5	5	¥
			7/31/01	7/31/01		10	10	10		Research - National government (US or Foreig	National g	overnment	(US or Fe	reig
Baker, Robert Owen	9931210	Regular	00/90/1	1/16/01	18			T 12-57	J					
			9/18/01			10	10	∞	: .	Remain at Host Agency	lost Agent	Ś		
Baranyi, Lajos	9716730	Senior	6/22/98	6/21/01	36	(C)	3	2	1					
			7/09/01			6	6	8		Remain at Host Agency	Host Agen	cy		-
Biba, Edmond	9926460	Regular	66/87/9	8/27/01	26			j.		2	2	3	t	NC
				10/11/01										in the second
Bosio, Catharine Mans	0035870	Regular	9/11/00	8/31/01	12	-	•	-			-			
			10/16/01			10	10	10		College or University Professor	University	Professor		
Bosio, Christopher Francis	9822750	Regular	2/04/99	8/31/01	31		AND THE PROPERTY OF THE PROPER							
Byrd, Wyatt	9716580	Senior	1/20/98	1/19/01	36									
Dutta, Sheetij	9818400	Regular	7/27/98	7/26/01	36	3	3	•	2					
	filipini Nation		11/06/01			10	10	10		Remain at Host Agency	Host Agen	cy	A) Vi	
Hensley, Lisa Ellen	9820060	Regular	9/01/98	11/30/00	27	_	2	3						
			11/29/00			10	8	8		Remain at Host Agency	Host Agen	cy		
Hulet, Stanley Warren	9931110	Regular	00/01/1	9/28/01	21	1	I				American de la constanta de la			
			9/20/01			10	10	10		Industry				
Jenner, Jennifer Louise	9819910	Regular	86/10/9	5/31/01	36	1	3	•	•					
			5/21/01			10	7	10		Research - National government (US or Foreig	National g	overnmen	t (US or F	oreig
Jensen, Melody Janet	9822730	Senior	8/10/98	00/02/6	26	7.4			Notice that the second					
						Y.								

^{* &}quot;Mnths" reflects the actual months the Associate was on Tenure accounting for leave of absences, etc. between the first award date and final termination date.

U.S. Army Medical Research and Materiel Command For Associates Who Ended Tenure Between

12/12/2001 Page 2 of 3
[r_term_summary] .

Name	Id Number Level	Level	Start		Mnths*	Journal Articles	Presentations Domestic Intl	Ι,	Patents	Know	Tech	Motiv	Rsch	Colleg
			Term Rpt Received	Advr Rpt Received		Career		NRC		Post-Tenure Plans	Plans			
Kanjilal, Partha Partim	9824290	Senior	8/02/99	7/20/01	24		3		ı	5	5	4	4	\\\\\
			7/27/01	5/23/01		8	8	8		Other				
Korolev, Sergey Vasilyevich 9929010	9929010	Regular	66/10/6	4/14/01	19	ŧ		1	1	\$	5	5	\$	Y
			6/12/01	6/28/01		∞ :	10	10		Remain at Host Agency	lost Agenc	λ.		
Kwik, Jeanne Frieda	0037600	Regular	00/50/9	8/31/01	15	1		-	•					
			10/03/01			8	5	8		College or University Professor	Jniversity	Professor		
Leader, Haim Nissan	9823600 Senior	Senior	66/01/5	11/09/00	18		3			2	5	5	\$	Y
			10/18/00	10/18/00 12/22/00		6.	6	10		Research - National government (US or Foreig	Vational go	overnment	(US or F	oreig
Markotic, Alemka	9928440	Regular	10/25/99	10/24/00	12	•								
			10/03/00							Research - National government (US or Foreig	National g	overnment	(US or F	oreig
Marvaud, Jean-Cristophe	9925411	Regular	12/01/99	11/30/00	12	10	. &	- 8		Research - National government (US or Foreig	4 National g	4 overnment	4 (US or F	Y oreig
Mendelson, Itai	9930040	Senior	4/24/00	6/30/01	14		2			4	5	2	5	Y
			6/13/01	8/16/01		10	10	10		No Information provided	tion provic	ded		
Rayner, Jonathan Ole	0035650	Regular	5/01/00	10/31/00	9	. ∞	•	- 10		Industry				
Waitumbi, John Njenga	9716480	Senior	2/09/98	2/08/01	36	-	2	2	1					
			3/07/01			10	10	8		Remain at Host Agency	lost Agen	cy	:	

^{* &}quot;Mnths" reflects the actual months the Associate was on Tenure accounting for leave of absences, etc. between the first award date and final termination date.

U.S. Army Medical Research and Materiel Command For Associates Who Ended Tenure Between

12/12/2001 Page 3 of 3 [r_term_summary] •

					Dates		Journal	Presentations	tions						
Name	Id Number Level	er L	•		Term	Mnths*	Articles	Domestic	Intl	Patents	Know	Tech	Motiv	Rsch	Colleg
			Terr Rec	Term Rpt Received	Advr Rpt Received		Career	Lab	NRC		Post-Tenure Plans	e Plans			
Weeks, Steven Douglas	9820000	i	Regular 5/	5/04/98	5/03/01	36									Group (Gales Cales (1997)), pressed
															. •
				-	. :		:			i i					
Totals for	Date Calcuations	suo	Froi	From Assoc Report	Report		From A	From Adviser Report	ort		Sun	ımary of I	Summary of Post Tenure Plans	e Plans	
AMRMC				Totals	s Average	эвг		Totals	Totals Average		Research - National government (US or Fo 5	onal gove	mment (U	S or Fo 5	78%
	Average:	23	Total		17 7	77%	Total	11 7	32%		Remain at Host Agency	Agency		9	35%
	Max:	36	Jrnl Art	Ħ	.0 6	0.53	Knowledge	e 30	4.29	Col	College or University Professor	versity Pro	fessor	2	12%
	Min:	9	Domestic		26 1.	1.53	Technique	e 31	4.43	Other	er			_	%9
	Std Dev:	10	10 International		12 0.	0.71	Motivation	n 31	4.43	Indi	Industry			(1	12%
			Patents	S.	2 0.	0.12	Indpendence	e 32	4.57	N _o	No Information provided	ı provided			%9
				Median	n Average	<i>a</i> 8.		Totals	Totals Average				Ţ	Totals: 17	1-
Number of Ter	Number of Terminated Assocs: 22	s: 22	Career		10 9.38	38	Colleg = Y	9 ,	%98						
			Lab		10 8.88	88	Colleg = N	•	%0						
			NRC		10 9.13		Colleg = No Cmt	-	14%						

^{* &}quot;Mnths" reflects the actual months the Associate was on Tenure accounting for leave of absences, etc. between the first award date and final termination date.

AMRMC: Medical Res Inst of Chemical Defense For Associates Who Ended Tenure Between

12/12/2001 Page 1 of 6 [r_term_summary] .

				Dates		Journal	Presenta	tions						
Name	Id Number Level Start	Level	Start	ı	Term Mnths*	Articles	* Articles Domestic Intl Patents Know Tech Motiv Rsch Colleg	Intl	Patents	Know	Tech	Motiv	Rsch	Colleg
			Term Rpt / Received I	Advr Rpt Received		Career	Career Lab NRC	NRC		Post-Tenure Plans	e Plans			
Hulet, Stanley Warren	9931110 Regular 1/10/00	Regular	1/10/00	10/87/6	21		_	•	•					
			9/20/01			10	10	10		Industry				

Totals for	Date Calcuations	ions	From Assoc Report	soc Re	port	From Adviser Report	ser Rep	ort		Summary of Post Tenure Plans
MRICD		Ī	TC	Totals	Average		Totals	Totals Average	Industry	1 100%
	Average:	21	Total	-	100%	Total	ı	%0		Totals: 7
	Max:	21	Jml Art		0.00	Knowledge	•			
	Min:	21	Domestic	-	1.00	Technique	,			
	Std Dev:	0	0 International	•	0.00	Motivation	•			
			Patents	1	0.00	Indpendence	ı			
			Me	Median ,	Average		Totals	Totals Average		
Number o	Number of Terminated Assocs: 1	ocs: 1	Career	10	10.00	Colleg = Y	1			
			Lab	10	10.00	Colleg = N	ı			
			NRC	10	10.00	10.00 Colleg = No Cmt	•			

^{* &}quot;Mnths" reflects the actual months the Associate was on Tenure accounting for leave of absences, etc. between the first award date and final termination date.

AMRMC: Medical Research Institute of Infectious Diseases For Associates Who Ended Tenure Between

				Dates		Journal	Presentations	ions						
Name	Id Number Level	Level	Start	4	Mnths*	Articles 1	Domestic	Intl	Patents	Know	Tech	Motiv	Rsch	Colleg
			Term Rpt Received	Advr Rpt Received		Career	Lab	NRC		Post-Tenure Plans	. Plans			
Baker, Robert Owen	9931210 Regular 1/06/00	Regular	00/90/1	10/91/2	81			-						
Bosio Catharine Mans	0035870	Regular	9/18/01	8/31/01	- 1	0.	0	& -		Remain at Host Agency	lost Agenc	À		
		0	10/16/01		1	10	10	101		College or University Professor	Iniversity	Professor		
Rosio Christonher Francis	9877750	Remiar	2/04/99	8/31/01	21	2				compete or	Juiveisity	1 10103301		
		rvg mar			7									
Hensley, Lisa Ellen	9820060	Regular	9/01/68	11/30/00	27	-	2	3	•					
			11/29/00	:		10	8	8		Remain at Host Agency	lost Ageno	ķ		
Jensen, Melody Janet	9822730	Senior	86/01/8	9/30/00	26									
Kwik, Jeanne Frieda	0037600	Regular	00/50/9	8/31/01	15	1		П	1					
			10/03/01			∞	5	8		College or University Professor	Jniversity	Professor		
Markofic, Alemka	9928440 Regular 10/25/99 10/24/00	Regular	10/25/99 10/03/00	10/24/00	7	•		T		Research - National government (US or Foreig	National g	эустиен	t (US or F	oreig
Marvaud, Jean-Cristophe	9925411	Regular	12/01/99	11/30/00	12	,	-	l	-	4	4	4	4	Y
				1/08/01		10	8	8		Research - National government (US or Foreig	National g	overnmen	t (US or F	oreig
Mendelson, Itai	9930040	Senior	4/24/00 6/13/01	.6/30/01 .8/16/01	14	.		01		4 5 No Information provided	5 tion provi	5 Jed	5	λ
Rayner, Jonathan Ole	0035650	Regular	5/01/00	10/31/00	9	•	-							
						8	8	10		Industry				

^{* &}quot;Mnths" reflects the actual months the Associate was on Tenure accounting for leave of absences, etc. between the first award date and final termination date.

AMRMC: Medical Research Institute of Infectious Diseases For Associates Who Ended Tenure Between

12/12/2001 Page 3 of 6 [r_term_summary]

									-					
				Dates		Journal	Presenta	suon						
Name	Id Number Level	Level	Start	Term	Mnths*	Articles j	Domestic Intl	Intl	Patents	Patents Know	Tech	Motiv	Motiv Rsch Colleg	Colleg
			Received Rec	Advr Kpt Received		Career	r Lab	NRC		Post-Tenure Plans	Plans			
Weeks, Steven Douglas	9820000 I	Regular	\$/04/98	5/03/01	36									

Totals for	Date Calcuations	ions	From Assoc Report	ssoc Re	port	From Adviser Report	iser Rep	ort	From Adviser Report Summary of Post Tenure Plans	
MRIID			L	Totals	Average		Totals	Totals Average	Research - National government (US or Fo 2 25%	2 25%
	Average:	19	Total	7	64%	Total	2	18%	Remain at Host Agency	2 25%
	Max:	36	Jml Art	-	0.14	Knowledge	∞	4.00	College or University Professor	2 25%
	Min:	9	Domestic	9	0.86	Technique	6	4.50	Industry	1 13%
	Std Dev:	6	9 International	∞	1.14	Motivation	6	4.50	No Information provided	1 13%
			Patents	•	0.00	Indpendence	6	4.50	Totals:	_ ∞
			M	edian	Median Average		Totals	Totals Average		
Number of To	Number of Terminated Assocs: 11	ss: 11	Career	10	9.43	Colleg = Y	2	100%		
			Lab	∞	8.43	Colleg = N	1	%0		
			NRC	∞	8.86	Colleg = No Cmt	•	%0		